Brachydactyly, a classic finding of severe hyperparathyroidism, is rarely seen in the current era of management of mineral and bone disorders of chronic kidney disease. This patient, a 49-year-old man with end-stage renal disease on hemodialysis for 10 years, had severe, uncontrolled tertiary hyperparathyroidism. When these radiographs were obtained in 1998, serum calcium level was 2.8 mmol/l (normal 2.2-2.5 mmol/l), serum phosphorus level was 1.5 mmol/l (0.8-1.4 mmol/l), and bone alkaline phosphatase level was 2,430 U/l (24-146 U/l). Parathyroid hormone (PTH) level was 4241 pg/ml (9.4-49 pg/ml), measured using a first-generation intact 1-84 PTH assay. He had a long history of nonadherence to dietary phosphorus restriction, as well as to the use of oral phosphate binders; he refused parathyroidectomy. Due to persistent hypercalcemia, active vitamin D therapy could not be administered, and aluminum hydroxide had been substituted for calcium-containing phosphate binders. Figure 1a demonstrates subperiosteal resorption of the phalanges, best seen along the radial aspects of the right second and third middle phalanges (thick arrows), and osteolysis of multiple phalangeal tufts, as highlighted in the left second distal phalanx (thin arrow). Soft-tissue calcification (asterisk) and coarsened trabecular pattern are also found. Figure 1b illustrates pseudoclubbing due to shortened distal phalanges. With the advent of new therapeutic agents such as non-calcium-based phosphate binders, vitamin D analogs, and calcimimetic therapy, severe tertiary hyperparathyroidism of this magnitude occurs less frequently, and these characteristic findings are not as common as in years past. 
